ITMCTR1900002628尚未招募4 期
A prospective, multicenter, randomized, open study on the efficacy and safety of Yisaipu combined with traditional Chinese medicine for standard treatment and maintenance therapy in RA patients who failed traditional DMARDs treatment
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 65（—）
- 性别
- All
入选标准
- •Subjects must meet the following criteria to be enrolled in this study:
- •1. Male or female aged 18-65 (including 18 or 65);
- •2. RA classification standards revised by American college of rheumatology in 2010;
- •3. ACR joint function level I, II or III;
- •4. At least 12 weeks before enrollment, conventional synthetic DMARDs failed to achieve clinical remission or low disease activity, and had not received biological agents treatment;
- •5. If subjects are treated with NSAIDs or other analgesics, they must be treated with a stable dose of at least 2
- •6. If oral glucocorticoids are administered, the dose must be stabilized to the equivalent for at least 4 weeks prior to enrollment before the study drug is first administered dose <= 10mg prednisone /day. If glucocorticoid is not used, oral glucocorticoid should not be taken at least 2 weeks before enrollment. After into the group allowed to reduce the amount, according to the needs of their own decision. Glucocorticoid can help control the disease. In order to avoid interfering with the disease, it must be stable in the first 2 weeks. After the selection, if the condition is better, can reduce the amount. Since the dose is small (<10mg/d), the reduction scheme can be determined by oneself. However, reduction is not encouraged and it is recommended to maintain the small dose.
- •7. Female and male subjects of reproductive age must use appropriate contraception during the study period and within 6 months after the last study administration. Childbearing age female subjects must have a negative pregnancy test;
- •8. Meet the following TB screening criteria:
- •1) no history of active tuberculosis;
- •2) no recent close contact with active TB patients;
- •3) no symptoms or signs of active TB were found in the medical history and physical examination;
- •4) chest radiographs taken within 3 months before enrollment (positive and lateral) proved no evidence of active tuberculosis;
- •5) within 6 weeks before enrollment, the tuberculin test should not exceed (++). If tuberculin test positive but can exclude active knot nuclear, start treatment simultaneously prevent anti-tuberculosis treatment (isoniazid + rifampicin) for 6 months;
- •9. Laboratory inspection standards:
- •1) hemoglobin >= 85g/L;
- •2) WBC leukocyte >= 3.5×10^9/L;
- •3) platelet >= 100×10^9/L;
- •4) serum aminotransferase and aminotransferase of glutamates were not more than 1.5 times the upper limit of normal value;
- •5) serum creatinine should not exceed 1.5mg/dL(133umol/L).
- •10. Agree to sign the informed consent, which must be signed before enrollment;
- •11. Agree to stop adjuvant therapy such as traditional Chinese medicine and acupuncture 2 weeks before enrollment and throughout the study period.
排除标准
- •Subjects meeting the following criteria will not be included in this study:
- •1. Having inflammatory diseases other than RA, including but not limited to psoriatic arthritis, ankylosing spondylitis and systemic lupus erythematosus;
- •2. Received intra-articular injection, intramuscular injection or intravenous glucocorticoid within 4 weeks before the first study;
- •3. Known allergy to isepp, methotrexate or Chinese medicine;
- •4. Prior to enrollment, biotherapy was used, including (but not limited to) isepurium, zack, ambanol, infliximab, enazepurium, and adamumab, perceizumab, toluximab and rituximab were treated.
- •5. Subjects who became pregnant, breast-fed, or planned to become pregnant or fathered during or after the study, or women or men with fertility requirements;
- •6. Active infection (including mycobacterium infection, opportunistic infection, etc.) 3 months before the first study;
- •7. Within 3 months before the first study, during the study, or within 6 months after the last study;
- •8. Positive for hepatitis b surface antigen, hepatitis c antibody or human immunodeficiency virus antibody;
- •9. Have symptoms or signs of severe, progressive or uncontrolled kidneys, liver, blood, gastrointestinal, endocrine, lungs, heart, nerves, mind or brain disease;
- •10. Complications or a history of heart failure, including asymptomatic heart failure;
- •11. Lymphoproliferative diseases, including lymphoma, or possible signs of lymphoproliferative diseases;
- •12. Have a known malignancy or a history of malignancy within the previous 5 years;
- •13. Organ transplantation;
- •14. Is participating in experimental studies of other drugs;
- •15. Other researchers considered it inappropriate to participate in the study.
研究者
相似试验
尚未招募
3 期
A prospective, randomized, open, multicenter study to evaluate the efficacy and tolerability of induction therapy with a single high-dose anti-T-lymphocyte globulin (ATG-Fresenius) in renal transplant patients with a kidney from a non-heart-beating donor and tacrolimus, mycophenolate mofetil, and steroids as basic immunosuppression.delayed graft functionacute rejction10038430NL-OMON30577Academisch Medisch Centrum180
进行中（未招募）
不适用
A prospective, randomized, open, multicenter study to evaluate the efficacy and tolerability of induction therapy with a single high-dose anti-T-lymphocyte globulin (ATG-Fresenius) in renal transplant patients with a kidney from a non-heart-beating donor and tacrolimus, mycophenolate mofetil, and steroids as basic immunosuppression. - NHB-ATGTransplantation of a renal graft from a non-heart-beating donorEUCTR2007-000210-36-NLMC St Radboud University Hospital Center
已完成
不适用
Mycophenolate sodium versus Everolimus or Cyclosporine with Allograft Nephropathy as OutcomeRenal transplantSurgeryTransplanted organs and tissue statusISRCTN69188731Academic Medical Center (AMC), Renal Transplant Unit (The Netherlands)255
已完成
不适用
CAlciNeurin-inhibitor Nephrotoxicity and Efficacy StudyRenal transplantInjury, Occupational Diseases, PoisoningFailure and rejection of transplanted organs and tissuesISRCTN55817881eiden University Medical Centre (LUMC) (The Netherlands)126
进行中（未招募）
不适用
A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. - PURETHAL Grasses Rush studyAllergic (IgE-mediated) rhinitis/rhinoconjunctivitis due to sensitization to grass pollenMedDRA version: 12.0Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisMedDRA version: 12.0Level: LLTClassification code 10001726Term: Allergic rhinitis due to pollenMedDRA version: 12.0Level: LLTClassification code 10053741Term: Allergenic desensitization procedureEUCTR2009-015012-18-DEHAL Allergy BV